Ezetimibe, which blocks intestinal absorption of dietary cholesterol, further reduces LDL cholesterol in patients who have not achieved target levels on statin therapy.
Dr. Barry Gumbiner from Merck and Company, Inc., Rahway, New Jersey, and colleagues from the Ezetimibe Study Group randomly assigned 769 patients with primary hypercholesterolemia, who had been receiving statin therapy for 6 or more weeks, to concurrent treatment with ezetimibe 10 mg/day or placebo.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!